TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effect of Dexmedetomidine on Phenylephrine Response During Refractory Septic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years old~* Septic shock, defined by the Sepsis-3 criteria~  * proven or suspected infection, with modification of the SOFA score ≥ 2 points,~ * with persistent hypotension requiring vasopressors to maintain MAP ≥ 65 mmHg~ * and a serum lactate level \> 2 mmol/L despite adequate vascular filling~* Adequate vascular filling: ≥ 30ml/kg, OR absence of preload-dependency criteria at time of assessment (respiratory variability of the inferior vena cava, passive leg lift, pulsed pressure variation)~* Catecholamine resistance, defined by the need for a dose of norepinephrine ≥ 0,5 µg/kg/min for more than 2 consecutive hours within 24 hours of admission to intensive care unit~* persistence of circulatory failure with at least one of the following criteria present in the 2 hours prior to randomisation: hyperlactatemia \> 2mmol/l, and/or mottling (≥ 1 score), and/or oliguria (diuresis \< 0,5 ml/kg/h over the last 2 hours)~* Invasive Mechanical ventilation~* Under sedation by midazolam or propofol~* Informed consent obtained from a relative for patient included in an emergency~* Patient affiliated to the national health insurance system~Exclusion Criteria:~* Cardiac arrest before inclusion and occurring before septic shock criteria are met~* Cardiac index \< 2.2 l/min/m² after volume correction, or left ventricular ejection fraction \< 40% on echocardiography~* Bradycardia \< 55 bpm (apart from treatment with β-blocker) or 2nd or 3rd degree BAV not equipped~* Proven or suspected decompensation of coronary heart disease~* Acute cerebrovascular condition within 2 weeks prior to inclusion~* Severe hepatic insufficiency with TP and factor V \<50% in the absence of DIC (disseminated intravascular coagulation)~* Patient on adrenaline or vasopressors at the time of inclusion (epinephrine or vasopressin stopped prior to inclusion is not a criterion for non-inclusion)~* Patient on non-selective MAOI iproniazid within 15 days of inclusion~* Patient for whom a decision has been made to limit the use of therapies~* Hypersensitivity to dexmedetomidine or phenylephrine~* Patient on dexmedetomidine before inclusion~* Person subject to a legal protection measure (curatorship, guardianship)~* Person subject to limited judicial protection~* Pregnant, parturient or breastfeeding woman~* Patient with suspected or confirmed mesenteric ischemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transcranial Magnetic Stimulation: Treatment Trial for Depressed Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV Major Depressive Episode of no more then 3 years.~* Montgomery-Asberg Depression Rating Scale score of 20 or more.~* Aged between 13 and 18.~* May or may not be taking antidepressant medication.~Exclusion Criteria:~* Patient (or family is patient is under 18)not able to give informed consent.~* Failure to respond to ECT in current or past episodes of depression.~* Significant other Axis 1 psychiatric disorders e.g. schizophrenia.~* In imminent physical or psychological danger and needs a rapid clinical response due to inanition, psychosis or high suicide risk.~* Drug or alcohol abuse currently or in the last month.~* History of neurological illness e.g. epilepsy; neurosurgical procedure~* Mental in the cranium, a pacemaker, cochlear implant, medication pump or other electronic device.~* Women of child-bearing age whom pregnancy cannot be ruled out.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Correlation Between Peripheral Venous Pressure and Central Venous Pressure in the Cardiac Intensive Care Unit

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* We plan to enroll patients who meet the following criteria: Patients admitted to an intensive care unit for invasive hemodynamic monitoring. All eligible patients will be those who have already undergone pulmonary artery catheterization via the internal jugular or subclavian veins and upper extremity peripheral IV placement per routine standard of care prior to enrollment.~Exclusion Criteria:~* Patients will be excluded from this study for the following reasons: age less than 18 years of age, inability to obtain consent, femoral pulmonary artery catheter, or if their attending physician refuses to allow enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Valproic Acid and Dihydroergotamine as Abortive Therapy in Pediatric Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* acute migraine as per ICHD-II criteria~* pediatric (age 10-18)~Exclusion Criteria:~For Valproic Acid (VPA)~* Pregnancy~* Liver disease (Acute or Chronic)~* Urea Cycle Disorder~* Mitochondrial Disease~For Dihydroergotamine (DHE)~* Pregnancy~* Peripheral vascular disease, coronary heart disease~* History of cerebrovascular event~* Severe or poorly controlled hypertension~* Impaired liver or renal function~* Triptan given in last 24 hours~* Hemiplegic migraine

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Cross-Over to Dihydroergotamine (Type: ACTIVE_COMPARATOR): An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels. Patients who do not respond to VPA after 24 hours will be given Dihydroergotamine (DHE) for the next 24 hours. Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose \>1mg and not exceeding 3mg over 24 hours.
- Cross-Over to Valproic Acid (Type: ACTIVE_COMPARATOR): Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose \>1mg and not exceeding 3mg over 24 hours. Patients who do not respond to DHE after 24 hours will be given Valproic Acid (VPA) for the next 24 hours. An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.
- Valproic Acid (Type: ACTIVE_COMPARATOR): An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.
- Dihydroergotamine (Type: ACTIVE_COMPARATOR): Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose \>1mg and not exceeding 3mg over 24 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Elucidation of Acid-Induced Pulmonary Inflammation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. chronic cough consistent with bronchoreactivity~2. Gastroesophageal reflux~Exclusion Criteria:~1. Severe asthmatics who have been hospitalized within the last 6 months or who have required oral steroid use within the last 4 weeks~2. Severe coronary artery disease~3. Cigarette/cigar smoking within the last 6 months~4. Documented allergies affecting the respiratory system~5. Subjects with contraindications to pH/impedance probe~   1. Hemophilia~  2. Septal deviation~6. Subjects with contraindications to bronchoscopy as outlined by the American Thoracic Society Guidelines~7. Anticoagulation~8. Pregnancy~9. Incarcerated patients~10. Current oral steroid use (may suppress levels of inflammation)~11. Upper respiratory infection within the last 2 weeks~12. Ongoing acid suppression with a proton pump inhibitor, however, patients may be included if they have discontinued their proton pump inhibitor within the last 1 month with stable asthma symptoms as defined by stable utilization of inhaled steroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lansoprazole therapy (Type: ACTIVE_COMPARATOR): Lansoprazole 30 mg orally twice daily
- Placebo (Type: PLACEBO_COMPARATOR): placebo orally twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:Inclusion Criteria~* Age 18 - 75 yrs~* Male or non-pregnant/non-lactating female~* Subjects must have a mean attack frequency of at least 3 episodes/day of 4/10 pain~* Use of adequate birth-control measures as determined by investigator for females of child-bearing potential~* Diagnosis of Classical trigeminal neuralgia (TN) using International Classification of Headache Disorders (ICHD-2) criteria (see Appendix A in Protocol)~* Subjects have given written informed consent prior to entering study~* Subjects on a stable dose of concomitant preventive medications for treatment of TN for at least 4 weeks prior to study entry and throughout the 12 week observation period~* Subjects who require rescue analgesic medication during the study will be allowed to use their current (pre-study) opioid and/or non opioid analgesics as clinically indicated (e.g., non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, cyclooxygenase-2 (COX-2) inhibitors, topical analgesics).~* Subjects will be prohibited from initiating any therapy with a new preventive medication throughout the remainder of the study.~* Subject must be willing and able to abstain from initiating an alternative therapy (e.g., acupuncture, massage or physical therapy) for pain relief during the study.~(NOTE: subjects who are currently using alternative therapy for pain relief can be enrolled if they are willing and able to maintain such therapy stable throughout the study.)~-~Exclusion Criteria:Exclusion Criteria~* Symptomatic TN~* Serious hepatic, respiratory, hematologic, cardiovascular or renal condition~* Neurologic pain other than TN, with the exception of occasional migraine or tension-type headaches. (\<4 headaches per month; \< 10 headache days/month)~* Psychiatric or medical condition that might compromise participation in study, as determined by the investigator~* Administration of any investigational drug within 30 days prior to screening~* History of substance abuse/alcoholism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Incobotulinumtoxina (Type: ACTIVE_COMPARATOR): Xeomin 25-100 units injected to chosen area one time.
- Placebo Comparator (Type: PLACEBO_COMPARATOR): Placebo Comparator is 1-2 ml normal saline solution injected to chosen area one time.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Double-Blind Placebo Controlled Trial to Determine the Status of Post Knee Chondroplasty Patients Administered Theramine Versus Placebo in Addition to Post Surgery Analgesics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed knee pain requiring chondroplasty knee arthroscopic surgery.~* Men and non-pregnant, non-lactating women over the age of 18 and under the age of 75, able to read, understand and sign English-language informed consent.~* If using psychoactive medication which might have analgesic effects, (i.e. anti-depressants or anti-consultants), treatment must be stable for at least three (3) months prior to study.~* For men and women of child-bearing potential, must be willing to use adequate contraception and not be pregnant or impregnate their partner during the entire time of study.~* Must be willing to commit to all clinical visits during study-related procedures.~* Require use of narcotics for pain relief.~Exclusion Criteria:~* Patients with significant neurologic impairment, as diagnosed on screening physical examination.~* Patients not fluent in English.~* Patients currently involved in a Workman's Compensation case related to this procedure.~* Receipt of an oral intramuscular or soft-tissue injection of corticosteroid within one (1) month prior to screening.~* History of substance abuse.~* History of malignancy, other than basal or squamous cell of the skin within the last 5 years.~* Tibial plateau fracture within 6 months prior to surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Theramine (Type: ACTIVE_COMPARATOR): Theramine 2 capsules three times per day in addition to post surgical analgesic medication.
- Theramine-like Placebo (Type: PLACEBO_COMPARATOR): Theramine-like placebo 2 capsules three times per day in addition to post surgical analgesic medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Natural History of Human Papillomavirus (HPV) Infections in Adult Women With Recurrent Conizations in Norway

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~All subjects must meet the following criteria at study entry:~* Women aged 18 years and above at the time of the collection of the primary cone specimen;~* Who have undergone for the first time a conization due to high grade lesions or microinvasive cervical carcinomas, histologically diagnosed in 2003, with possible extension backwards in time;~* Availability of recurrent cone specimen with high grade lesions/ microinvasive cervical carcinomas or invasive cervical cancer;~* Availability in designated local laboratories of the primary and recurrent cone specimens;~* The cone specimen was adequately preserved;~* Written informed consent obtained from the subject. If the subject is deceased, the cone and biopsy specimens will be used according to prior approval from the Ethics Committee.~Exclusion Criteria:~None.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: None): Women aged 18 years and above, diagnosed with high grade lesions or microinvasive cervical carcinomas in primary conization performed and registered in the Cancer Registry of Norway, and presenting with recurrent conization with high grade lesions or microinvasive cervical carcinoma or invasive cervical carcinoma.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Platelet Transfusion in Patients on Antiplatelet Therapy With Traumatic Head Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* Evidence of intracranial hemorrhage (bleeding in the brain) by CT scan related to traumatic injury~* Receiving antiplatelet therapy such as aspirin, thienopyridine (ticlopidine, clopidogrel, or prasugrel)~* Platelet count greater than or equal to 100,000~Exclusion Criteria:~* Glasgow Coma Scale (GCS) less than 6~* Hemorrhage requiring emergent surgery~* Lack of permission from treating physician and/or consultant~* Secondary ICH related to aneurysm or arteriovenous malformation~* Use of oral anticoagulants~* Decreased platelets (thrombocytopenia)~* Patients requiring massive transfusion protocol~* Life expectancy less than 3 months~* Confirmed acute heart attack~* Hepatitis and liver cirrhosis~* Kidney failure~* Participation in another treatment study within the preceding 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Saline (Type: PLACEBO_COMPARATOR): 400 mL of Saline will be given intravenously over 2 hours once.
- Platelets (Type: ACTIVE_COMPARATOR): 2 apheresis units of platelets (approximately 200 ml) will be given intravenously over 2 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Artesunate Plus Sulfadoxine-pyrimethamine Pharmacokinetics, Efficacy, Gametocytes Carriage and Birth Outcomes in Pregnant Women With Malaria

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant female, older than 18 years, \> 35kg.~* Gestational age \> 16 weeks (fundal height \> 16cm) and below 36 weeks gestation.~* Diagnoses of uncomplicated acute P. falciparum malaria parasitaemia of up to 250 000 asexual parasites/ul blood with axillary temperature of greater than or equal to 37.5°C or history of fever (defined as fever within the previous 24 hours).~* Documented written informed consent.~* Lives close enough to the study site for reliable follow up and is willing to attend ANC and follow-up visits regularly.~* Is willing to stop taking folate for 7 days if applicable.~Exclusion Criteria:~* Has received anti-malarial treatment in the past 7 days.~* Severely ill (based on WHO Criteria for severe malaria ) or if patient is considered, in the opinion of the investigator or designee, to have moderately severe malaria (e.g. prostrate, repeated vomiting, dehydrated) or other danger signs (Appendix 2).~* Known hepatic or renal impairment~* Has received chloramphenicol or tetracyclines (including doxycycline) in the past 7 days or is likely to require these during the study period.~* History of G6PD deficiency.~* Has a history of allergy to any of the study drugs (including other sulphonamides e.g. cotrimoxazole, or other artemisinin derivatives e.g. co-artemether).~* Serious underlying disease that in the opinion of the clinic team and/or Principal Investigator would make the patient unsuitable for the study in terms of their safety or study analysis.~* Imminent delivery expected.~* Prior inclusion in this study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Artesunate plus sulphadoxine-pyrimethamine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females with pathologically determined locally advanced or metastatic human epidermal growth factor receptor 2 positive (HER2/neu+) breast cancer~* Have progressed after treatment with chemotherapy including a taxane and trastuzumab~* Must have measurable disease by RECIST~* ECOG PS of 0,1, or 2~* MUGA scan or echocardiogram results show left ventricular ejection fraction greater than or equal to 50%~Exclusion Criteria:~* Radiation therapy within 2 weeks, chemotherapy within 3 weeks, or noncytoxic investigational agents within 4 weeks of initiating study treatment~* Evidence of New York Heart Association class III or greater cardiac disease~* History of MI, stroke, ventricular arrhythmia, or symptomatic conduction abnormality~* History of congenital QT prolongation~* Concurrent severe or uncontrolled medical disease~* Symptomatic central nervous system metastases~* Pregnant or nursing women~* Hypersensitivity or intolerance to apricoxib, lapatinib, capecitabine, 5-FU, sulfonamides, aspirin, or NSAIDs~* Severe renal insufficiency~* History of upper GI bleeding, ulceration, or perforation- Concurrent use of potent CYP3A4 inhibitors and CYP3A4 inducers~* Prior treatment with capecitabine~* Patients on anti-arrhythmic treatment~* Prior lapatinib therapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): apricoxib + lapatinib + capecitabine
- B (Type: PLACEBO_COMPARATOR): placebo + lapatinib + capecitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues